VYNDAQEL (TAFAMIDIS MEGLUMINE) — FDA Approval NDA211996 (FOLDRX PHARMS)
VYNDAQEL (TAFAMIDIS MEGLUMINE) — FDA Approval NDA211996 (FOLDRX PHARMS) is one of 9,000 drug approvals in the DrugApprovals dataset. Key details — Brand name: VYNDAQEL; Active ingredients: TAFAMIDIS MEGLUMINE; Application number: NDA211996.
| Brand name | VYNDAQEL |
|---|---|
| Active ingredients | TAFAMIDIS MEGLUMINE |
| Application number | NDA211996 |
| Sponsor | FOLDRX PHARMS |
| Dosage form | CAPSULE |
| Route | ORAL |
| Marketing status | Discontinued |
| Products in application | 1 |
| First approval date | 20190503 |
| Source | openFDA Drugs@FDA |
$1499/mo
Try DrugApprovals →